MedPath

Magnesium

Generic Name
Magnesium
Brand Names
Vitafol-one
Drug Type
Small Molecule
Chemical Formula
H2Mg
CAS Number
7439-95-4
Unique Ingredient Identifier
I38ZP9992A
Background

Magnesium is classified as an alkaline earth metal and has 2 hydration shells. The element can be found in abundance in the hydrosphere and in mineral salts such as dolomite and magnesium carbonate.

Common dietary sources of magnesium include nuts (cashews, peanuts, almonds), beans, bananas, apples, carrots, broccoli, and leafy greens. Magnesium is an important enzyme cofactor and is essential to several metabolic processes. Further, the mineral helps regulate blood pressure and is necessary for RNA, DNA and protein synthesis among several other functions.

Despite the importance of magnesium and its availability via several food sources, an estimated 56 to 68% of adults who live in developed, western countries do not meet the recommended daily intake (RDI) of magnesium. Several factors and common behaviours reduce the availability of magnesium in the diet such as food processing and cooking vegetables (which are normally a rich source of magnesium).

Indication

Healthy levels of magnesium can be achieved through a well balanced diet, but if food sources are insufficient, magnesium supplements can be used to prevent and treat magnesium deficiencies.

In medicine, various magnesium salts may be used in laxative and antacid products. For example, magnesium citrate is available over-the-counter and may be used to manage occasional constipation. Magnesium sulfate may be used on its own or with total parenteral nutrition to treat hypomagnesemia. Magnesium sulfate is also indicated to prevent seizures in pregnant women with pre-eclampsia, and to manage seizures associated with eclampsia.

Associated Conditions
Calcium Deficiency, Magnesium Deficiency, Zinc Deficiency

ADC189 Tablets on Influenza A Virus Infection/Influenza B Virus Infection

Phase 2
Completed
Conditions
Effect of Drug
Safety Issues
Interventions
Drug: 45 mg ADC189
Drug: 15 mg ADC189
Drug: Placebo
First Posted Date
2024-04-02
Last Posted Date
2025-01-21
Lead Sponsor
Jiaxing AnDiCon Biotech Co.,Ltd
Target Recruit Count
749
Registration Number
NCT06342921
Locations
🇨🇳

Rui Jin Hospital, Shanghai, Shanghai, China

Efficacy of Short Time Intervals in Split-Dose Bowel Preparation of Oral Sulfate Solution for Colonoscopy

Phase 4
Conditions
Colonoscopy: Bowel Preparation
Interventions
Drug: Magnesium Sulfate,Sodium Sulfate and Potassium Sulfate Concentrate Oral Solution
First Posted Date
2024-03-19
Last Posted Date
2024-03-19
Lead Sponsor
Changhai Hospital
Target Recruit Count
448
Registration Number
NCT06317597
Locations
🇨🇳

Changhai Hospital, Shanghai, China

PET Study to Evaluate Brain Receptor Occupancy, Safety and Pharmacokinetics of ITI-1284 in Healthy Subjects

Phase 1
Recruiting
Conditions
Healthy Volunteers
Interventions
Drug: ITI-1284 10 mg
Drug: ITI-1284 20 mg
First Posted Date
2024-03-07
Last Posted Date
2025-01-28
Lead Sponsor
Intra-Cellular Therapies, Inc.
Target Recruit Count
30
Registration Number
NCT06299410
Locations
🇺🇸

Clinical Site 1, New Haven, Connecticut, United States

Treatment of High-Risk Prostate Cancer Guided by Novel Diagnostic Radio- and Molecular Tracers

First Posted Date
2024-02-28
Last Posted Date
2024-02-28
Lead Sponsor
Cancer Research Antwerp
Target Recruit Count
493
Registration Number
NCT06282588
Locations
🇧🇪

AZ Groeninge, Kortrijk, Belgium

🇧🇪

GZA Sint-Augustinus, Wilrijk, Antwerp, Belgium

🇧🇪

OLVZ Aalst, Aalst, Belgium

and more 8 locations

A First-In-Human Study of Single and Multiple Ascending Doses of Oral SUL-238 in Healthy Subjects

Phase 1
Recruiting
Conditions
Healthy Subjects
Interventions
Drug: Single ascending doses SUL-238
Drug: Single dose Placebo
Drug: Single dose SUL-238
Drug: Multiple ascending doses SUL-238
Drug: Multiple doses Placebo
Drug: 2000 mg SUL-238 single dose for pharmacokinetics (food effect)
Drug: Single dose placebo (food effect)
First Posted Date
2024-02-26
Last Posted Date
2025-02-21
Lead Sponsor
GEN İlaç ve Sağlık Ürünleri A.Ş.
Target Recruit Count
83
Registration Number
NCT06277492
Locations
🇹🇷

Erciyes University IKUM Center, Kayseri, Turkey

Magnesium and Riboflavin Treatment for Post-Concussion Headache

Phase 2
Recruiting
Conditions
Concussion, Intermediate
Interventions
Drug: magnesium and riboflavin supplement
First Posted Date
2024-02-15
Last Posted Date
2025-03-27
Lead Sponsor
University of Virginia
Target Recruit Count
108
Registration Number
NCT06260072
Locations
🇺🇸

University of Virginia Student Health and Wellness Center, Charlottesville, Virginia, United States

Abuse Potential of HORIZANT With and Without Oxycodone in Healthy, Nondependent Recreational Opioid Users

Phase 4
Completed
Conditions
Abuse Potential
Interventions
Drug: Placebo
Drug: GE-IR 450 mg
Drug: GE-IR 200 mg
First Posted Date
2024-02-08
Last Posted Date
2024-08-12
Lead Sponsor
Arbor Pharmaceuticals, Inc.
Target Recruit Count
110
Registration Number
NCT06247488
Locations
🇺🇸

Altasciences Clinical Kansas, Overland Park, Kansas, United States

Administration of GV1001 for the Treatment of Progressive Supranuclear Palsy Who Completed Study GV1001-PSP-CL2-011

Phase 2
Active, not recruiting
Conditions
Progressive Supranuclear Palsy
Interventions
Drug: GV1001 Placebo
Drug: GV1001 1.12mg
First Posted Date
2024-02-01
Last Posted Date
2024-10-23
Lead Sponsor
GemVax & Kael
Target Recruit Count
67
Registration Number
NCT06235775
Locations
🇰🇷

Seoul National University Bundang Hospital, Seongnam-si, Korea, Republic of

🇰🇷

Kyung Hee University Hospital, Seoul, Korea, Republic of

🇰🇷

Samsung Medical Center, Seoul, Korea, Republic of

and more 2 locations

A Study of TG103 Injection in the Management of Non-diabetic Overweight or Obesity

Phase 2
Completed
Conditions
Obesity
Overweight
Interventions
Drug: TG103 7.5 mg
Drug: Placebo 15 mg
Drug: TG103 15 mg
Drug: TG103 22.5 mg
Drug: Placebo 22.5 mg
Drug: Placebo 7.5 mg
First Posted Date
2024-01-26
Last Posted Date
2025-05-14
Lead Sponsor
CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.
Target Recruit Count
314
Registration Number
NCT06226090
Locations
🇨🇳

Clinical Trials Information Group, Shijiazhuang, Hebei, China

Neurobiological Drivers of Mobility Resilience: The Dopaminergic System - Placebo-Controlled Arm

Phase 1
Completed
Conditions
Parkinsonian Signs in Older Persons
Interventions
Drug: Placebo 1
Drug: Carbidopa-Levodopa 25/100 mg
Drug: Placebo 2
First Posted Date
2024-01-23
Last Posted Date
2024-06-06
Lead Sponsor
University of Michigan
Target Recruit Count
13
Registration Number
NCT06219915
Locations
🇺🇸

University Hospital, Ann Arbor, Michigan, United States

🇺🇸

Domino's Farms, Ann Arbor, Michigan, United States

© Copyright 2025. All Rights Reserved by MedPath